Imeik Technology Development Co (300896) Q4 2024 earnings summary

Executive summary

• Achieved revenue of ¥3.03 billion in 2024, up 5.45% year-over-year; net profit reached ¥1.96 billion, up 5.47%.

• Maintained leading market share in sodium hyaluronate-based dermal fillers since 2018.

• Expanded product portfolio to 11 Class III medical devices, with strong R&D and patent output.

• Enhanced supply chain, digitalization, and warehouse automation to support growth.

• Received multiple industry awards and certifications for innovation and quality.

Financial highlights

• Operating income: ¥3,025.67 million, up 5.45% year-over-year.

• Net profit attributable to shareholders: ¥1,957.60 million, up 5.33% year-over-year.

• Operating cash flow: ¥1,927.17 million, down 1.38% year-over-year.

• Gross margin remained high at 94.66%.

• R&D investment: ¥303.68 million, 10.04% of revenue.

Outlook and guidance

• Plans to further invest in R&D, digital transformation, and production capacity in 2025.

• Expects continued growth in the medical aesthetics market, with a focus on innovation and international expansion.

• Dividend proposal: cash dividend of ¥38 per 10 shares, totaling ¥1.15 billion, representing 58.51% of 2024 net profit.